Drug
Tociliuzumab
Tociliuzumab is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 21 (50.0%)
N/A1 (50.0%)
Trials by Status
recruiting133%
completed267%
Recent Activity
1 active trials
Showing 3 of 3
completed
Tocilizumab in Refractory ASS-ILD
NCT07662265
recruitingnot_applicable
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
NCT07491913
completedphase_2
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
NCT04363736
Clinical Trials (3)
Showing 3 of 3 trials
NCT07662265
Tocilizumab in Refractory ASS-ILD
NCT07491913Not Applicable
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
NCT04363736Phase 2
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3